A Randomized Double-blinded Phase 2/3 Study of HB-202/HB-201 Alternating 2-Vector Therapy With Pembrolizumab Versus Pembrolizumab-Only for First Line HPV16+ High PD-L1 CPS Recurrent and/or Metastatic Oropharyngeal Squamous Cell Carcinoma

This is a study of HB-202/HB-201 alternating 2-vector therapy with pembrolizumab (also known as Keytruda®) in people with human papillomavirus subtype 16 positive (HPV16+) head and neck cancer starting in the middle part of the throat, who have not yet received systemic treatment after their cancer spread (metastatic) and/or returned (recurrent) and who are eligible to receive pembrolizumab.
Doctors already use pembrolizumab therapy (with or without chemotherapy) to treat head and neck cancer. However, the treatment does not work well in most people with this type of cancer. HB-202/HB-201 alternating 2-vector therapy with pembrolizumab, which is designated to stimulate a stronger immune attack against HPV16+ tumors, was shown to be safe and suggested to work better than pembrolizumab-only in a small number of participants with HPV16+ head and neck cancer (see H-200-001, NCT04180215).
This trial studies HB-202/HB-201 alternating 2-vector therapy with pembrolizumab in a much larger number of participants from different countries to confirm its benefits for people with HPV16+ head and neck cancer that started in the middle part of the throat compared with pembrolizumab-only therapy. This trial studies whether administering HB-202/HB-201 alternating 2-vector therapy with pembrolizumab works better in more participants by shrinking their tumors and makes them live longer than pembrolizumab-only therapy.
Participants will receive the study treatments by injection into a vein every 3 weeks during the first 3 months and then every 6 weeks until up to about 2 years, which will be followed by a long observation period to continue looking at the safety and clinical benefits after the last dose of study treatment.

开始日期2024-12-01

申办/合作机构

Hookipa Biotech AG

NCT06373380

/ Active, not recruiting早期临床1期IIT

A Pilot Study Evaluating HB-200 in Patients With Positive TTMV-HPV DNA After Definitive Treatment for HPV16 Positive HNSCC

The researchers are doing this study to find out if HB-202/HB-201 is a feasible treatment for people with HPV 16-positive head and neck squamous cell cancer (HPV 16+ HNSCC) who have received standard treatment for their disease but then tested positive for HPV 16-related tumor DNA in the blood through a test called NavDx. Participants will have no evidence of cancer on imaging scans (radiographically) or by medical examination (clinically). Past studies have shown that a positive NavDx test strongly suggests the possible presence of microscopic cancer, though we do not know if testing positive will definitely lead to the cancer coming back (recurrence). The NavDx blood test has not been approved by the FDA and is considered investigational.

开始日期2024-04-15

申办/合作机构

Memorial Sloan Kettering Cancer Center

[+2]

NCT05108870

/ Active, not recruiting临床1/2期IIT

A Randomized Phase I/II Trial of TheraT® Vectors Expressing HPV16 Specific Antigens in Combination With Neoadjuvant Chemotherapy Followed by Transoral Robotic Surgery or Risk/Response Stratified Chemoradiotherapy for Locoregional HPV16+ Oropharyngeal Cancer

Doctors leading this study hope to learn about the safety and effectiveness of combining medications HB-201 and HB-202 (also known as TheraT® vectors) with chemotherapy using carboplatin and paclitaxel in the beginning of the study (induction) and if combining these medications can increase tumor shrinkage after therapy and reduce the amount of radiotherapy and chemotherapy that will later be needed.
In addition, the study is looking at ways to reduce side effects overall using robotic surgery, chemotherapy and radiotherapy, or radiotherapy alone. Your participation in this research will last about 2 years.
HB-201 and HB-202 are experimental (meaning the US Food and Drug Administration (FDA) has not approved these drugs), and therefore they can only be given in a research study.

开始日期2022-08-22

申办/合作机构

The University of Chicago

100 项与 Eseba-Vec 相关的临床结果

登录后查看更多信息

100 项与 Eseba-Vec 相关的转化医学

登录后查看更多信息

100 项与 Eseba-Vec 相关的专利（医药）

登录后查看更多信息

项与 Eseba-Vec 相关的文献（医药）

2009-01-01·Journal of biomedical optics3区 · 医学

Broadband diffuse optical spectroscopy assessment of hemorrhage- and hemoglobin-based blood substitute resuscitation

3区 · 医学

ArticleOA

作者: Mahon, Sari ; Goldberg, Robert ; Saltzman, Darin ; Lee, Jangwoen ; Mukai, David ; Tromberg, Bruce J. ; Kim, Jae G. ; Patino, Renee ; Brenner, Matthew ; Kreuter, Kelly

Hemoglobin-based oxygen carriers (HBOCs) are solutions of cell-free hemoglobin (Hb) that have been developed for replacement or augmentation of blood transfusion. It is important to monitor in vivo tissue hemoglobin content, total tissue hemoglobin [THb], oxy- and deoxy-hemoglobin concentrations ([OHb], [RHb]), and tissue oxygen saturation (S(t)O(2)=[OHb][THb]x100%) to evaluate effectiveness of HBOC transfusion. We designed and constructed a broadband diffuse optical spectroscopy (DOS) prototype system to measure bulk tissue absorption and scattering spectra between 650 and 1000 nm capable of accurately determining these tissue hemoglobin component concentrations in vivo. Our purpose was to assess the feasibility of using DOS to optically monitor tissue [OHb], [RHb], S(t)O(2), and total tissue hemoglobin concentration ([THb]=[OHb]+[RHb]) during HBOC infusion using a rabbit hypovolemic shock model. The DOS prototype probe was placed on the shaved inner thigh muscle of the hind leg to assess concentrations of [OHb], [RHb], [THb], as well as S(t)O(2). Hemorrhagic shock was induced in intubated New Zealand white rabbits (N=6) by withdrawing blood via a femoral arterial line to 20% blood loss (10-15 cckg). Hemoglobin glutamer-200 (Hb-200) 1:1 volume resuscitation was administered following the hemorrhage. These values were compared against traditional invasive measurements, serum hemoglobin concentration (sHGB), systemic blood pressure, heart rate, and blood gases. DOS revealed increases of [THb], [OHb], and tissue hemoglobin oxygen saturation after Hb-200 infusion, while blood total hemoglobin values continued did not increase; we speculate, due to hyperosmolality induced hemodilution. DOS enables noninvasive in vivo monitoring of tissue hemoglobin and oxygenation parameters during shock and volume expansion with HBOC and potentially enables the assessment of efficacy of resuscitation efforts using artificial blood substitutes.

2008-03-01·American journal of therapeutics4区 · 医学

Measuring Circulating Blood Volume Using Infused Hemoglobin-Based Oxygen Carrier (Oxyglobin®) as an Indicator: Verification in a Canine Hypovolemia Model

4区 · 医学

Article

作者: Bezdikian, Vatche ; Jahr, Jonathan S ; Gunther, Robert A ; Lurie, Fedor ; Driessen, Bernd

BACKGROUND:

Direct determination of the circulating blood volume (CBV) is clinically desirable, especially when hemodynamic parameters such as blood pressure and heart rate are pharmacologically altered and may not be used with confidence for monitoring of CBV. In a rabbit model, we demonstrated that small volumes of hemoglobin-based oxygen carriers (HBOC) may be used for measuring of CBV with the indicator-dilution technique. This study aimed to verify the technique in a canine hypovolemia model with varying concentrations of infused HBOC.

METHODS:

Twenty-four healthy mongrel dogs were anesthetized and anesthesia maintained with isoflurane in 21% oxygen and sufentanil infusion. All animals were mechanically ventilated. After splenectomy and insertion of arterial, venous, and balloon-tipped pulmonary arterial catheters and recording of baseline values of total and plasma hemoglobin (Hb), hematocrit, and major hemodynamic parameters, dogs were bled (average 36.6 +/- 5.8 mL/kg) to a mean arterial pressure of 50 mm Hg and maintained hypovolemic for 1 hour. Thereafter, measurements were repeated, and dogs were resuscitated. Animals in group 1 were resuscitated with 30 mL/kg of 6% hetastarch solution (HES). Animals in other groups received either 10 mL/kg of Hb glutamer-200 (Hb-200; Oxyglobin) plus 20 mL/kg HES (group 2), 20 mL/kg Hb-200 plus 10 mL/kg HES (group 3), or 30 mL/kg Hb-200 (group 4). Solutions were infused at 30 mL/kg/hr. Measurements were repeated immediately after volume resuscitation. Plasma Hb concentration was determined after centrifugation using the HemoCue. Lactated Ringer's solution was infused in all subjects at 5 mL/kg/hr for maintenance. CBV at baseline was estimated as 85 mL/kg. CBV values immediately posthemorrhage were calculated by subtracting the volume of withdrawn blood from the baseline value. On the basis of the assumption that hemorrhage and subsequent volume resuscitation would not cause any hemolysis (as confirmed in group 1), all plasma Hb was considered to represent infused HBOC. The calculation of CBV using HBOC as an indicator was performed as previously published by Kasuya et al. CBV values derived from measured HBOC concentrations in plasma were compared with calculated (based on an original CBV of 85 mL/kg and withdrawn blood volume) values of CBV using the Bland-Altman analysis and by linear correlation. Agreement between the methods was analyzed by calculating the bias estimated by the mean difference and the standard deviation of the difference.

RESULTS:

Calculated and measured CBV values were highly correlated (r = 0.97). The difference between indicator dilution-derived and calculated values of CBV did not exceed 4% of calculated CBV in 97% of the measurements. The mean difference between measured and calculated values of CBV was 72 +/- 16 mL and did not vary significantly among groups 2, 3, and 4 (at varying concentrations of HBOC infused).

CONCLUSIONS:

In a canine hypovolemia model, knowing both the HBOC volume infused and the HBOC concentration measured in plasma allows for reliably determining the CBV. Our data verify the indicator-dilution technique with HBOC as an appropriate and clinically valuable method for monitoring CBV in treatment of hypovolemia.

2002-09-01·American journal of therapeutics4区 · 医学

Changes in Circulating Blood and Plasma Volume After Hemoglobin-Based Oxygen Carrier Infusion and Additional Infusion of Colloid Solutions

4区 · 医学

Article

作者: Jonathan S. Jahr ; Fedor Lurie ; Bernd Driessen

The aim of this study was to investigate the changes in circulating blood volume (CBV) after infusions of Hemoglobin glutamer-200 (bovine; Hb-200) in combination with 6% hetastarch in an animal model of acute posthemorrhagic anemia. Fifteen rabbits with a mean body weight of 2.2 +/- 0.2 kg were studied. After determination of the circulating plasma volume (CPV) and CBV, one third of the CBV was withdrawn via an arterial catheter. An equal volume of Hb-200 was then infused in the 5 animals in study group 1. In the remaining 10 animals, the same volume of 6% hetastarch solution was infused. Fifteen minutes after completion of the infusion, an additional infusion of 6% hetastarch at a dose equal to one third of the baseline CBV was performed in study group 1 and the control group. In study group 2, equal volumes of Hb-200 were infused. CPV measurements were performed at baseline, after hemorrhage, 5 and 15 minutes after volume replacement, and 1 and 15 minutes after hypervolemic hemodilution using the Evans blue dye dilution technique. The mean baseline CPV value was 53.4 +/- 1.1 mL/kg. The mean CBV at baseline was 90.8 +/- 4.9 mL/kg. After one third of the CBV was withdrawn, no differences in CBV or CPV were observed between the three groups. Replacement of one third of the CBV with Hb-200 significantly increased the CPV (73.7 +/- 1.8 mL/kg) when compared with the baseline level (53.5 +/- 1.8 mL/kg; n = 5; P < 0.05). The difference between the groups was first observed 15 minutes after infusion. CPV was significantly higher in study group 1 (87.0 +/- 2.2 mL/kg) compared with the other groups (80.2 +/- 2.6 mL/kg in the control group and 79.5 +/- 3.6 mL/kg in study group 2). After a second transfusion, the differences between the groups became more prominent. Study group 2 demonstrated the highest CPV and CBV. The two study groups demonstrated a statistically significant increase in circulating volumes compared with the control group. The magnitude of this difference was lower than expected based on in vitro colloid osmotic pressure measurements.

项与 Eseba-Vec 相关的新闻（医药）

2026-03-26

·GlobeNewswire-Health Care

HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics

Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail TherapeuticsNEW YORK and VIENNA, March 26, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”, the “Company”) today announced the completion of the sale of its immuno-oncology related assets, consisting primarily of the HB-200 (eseba-vec) and HB-700 development programs, to NeoTrail Therapeutics, Inc. (“NeoTrail”). The purchase price remains undisclosed. The asset purchase agreement was signed on January 28, 2026, and the closing of the transaction occurred on March 20, 2026. About HB-200 Eseba-vec (also known as HB-200) is an investigational immunotherapeutic agent being evaluated for HPV16 positive cancers. HB-200 alternates the administration of both HB-201 (LCMV) and HB-202 (PICV), collectively referred to as “HB-200,” attenuated viral vectors, which on their own are replicating-based therapeutics expressing a non-oncogenic, but highly immunogenic, E7E6 fusion protein from HPV16. Positive preliminary data from a Phase 2 trial (NCT04180215) of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16 positive head and neck cancers in the first line setting was presented in November 2024 at the Society for Immunotherapy of Cancer (SITC) Conference. Trial close out activities were completed before the end of 2025. HB-200 received Fast Track Designation from the U.S. Food and Drug Administration and PRIME designation from the European Medicines Agency. HB-200 was developed using HOOKIPA’s proprietary arenavirus platform. About HB-700HB-700 is an investigational arenaviral immunotherapy designed to treat KRAS-mutated lung, colorectal, pancreatic and other cancers. HB-700 is a replicating 2-vector therapy that targets the most prevalent KRAS mutations (G12D, G12V, G12R, G12C and G13D) and has the potential to benefit more patients than single mutation inhibitors. HB-700 received Investigational New Drug application clearance from the Food and Drug Administration in April 2024 and is Phase 1 ready, with clinical trial material manufacturing completed. Availability of Other Information About HOOKIPAInvestors and others should note that HOOKIPA announces material financial information to investors using the Company’s investor relations website, www.ir.hookipapharma.com, OTC Markets filings, press releases, public conference calls and webcasts. HOOKIPA uses these channels, as well as social media, to communicate with investors and the public about the company, and other issues. It is possible that the information HOOKIPA posts on social media could be deemed to be material information. Therefore, investors, the media, and others interested in HOOKIPA are encouraged to review the information on the social media channels listed on the Company’s investor relations website. For further information, please contact: IR@hookipapharma.com

免疫疗法临床2期快速通道临床1期疫苗

2026-02-03

·ir.hookipapharma.com

HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics

Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase price NEW YORK and VIENNA, Austria, Feb. 03, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”, the “Company”) today announced the sale of its immuno-oncology related assets, consisting primarily of the HB-200 (eseba-vec) and HB-700 development programs, to NeoTrail Therapeutics, Inc. (“NeoTrail”). The purchase price remains undisclosed. "We are delighted that the clinical development of these promising therapeutics will continue at NeoTrail with an opportunity to deliver patient benefit in multiple major market indications,” stated Mark Winderlich, Chief R&D Officer of HOOKIPA. The asset purchase agreement was signed on January 28, 2026, and the transaction is expected to close in the second quarter of 2026, subject to the satisfaction of customary closing conditions. About HB-200 Eseba-vec (also known as HB-200) is an investigational immunotherapeutic agent being evaluated for HPV16 positive cancers. HB-200 alternates the administration of both HB-201 (LCMV) and HB-202 (PICV), collectively referred to as “HB-200,” attenuated viral vectors, which on their own are replicating-based therapeutics expressing a non-oncogenic, but highly immunogenic, E7E6 fusion protein from HPV16. Positive preliminary data from a Phase 2 trial (NCT04180215) of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16 positive head and neck cancers in the first line setting was presented in November 2024 at the Society for Immunotherapy of Cancer (SITC) Conference. Trial close out activities were completed before the end of 2025. HB-200 received Fast Track Designation from the U.S. Food and Drug Administration and PRIME designation from the European Medicines Agency. HB-200 was developed using HOOKIPA’s proprietary arenavirus platform. About HB-700 HB-700 is an investigational arenaviral immunotherapy designed to treat KRAS-mutated lung, colorectal, pancreatic and other cancers. HB-700 is a replicating 2-vector therapy that targets the most prevalent KRAS mutations (G12D, G12V, G12R, G12C and G13D) and has the potential to benefit more patients than single mutation inhibitors. HB-700 received Investigational New Drug application clearance from the Food and Drug Administration in April 2024 and is Phase 1 ready, with clinical trial material manufacturing completed. Forward Looking Statements Certain statements set forth in this press release constitute “forward-looking” statements. Forward-looking statements can be identified by terms such as “anticipates”, “believes”, “expects”, “plans”, “potential”, “will”, “would” or similar expressions and the negative of those terms. Forward-looking statements in this press release include HOOKIPA’s statements regarding the expected closing of the asset purchase agreement and the therapeutic potential of HB-200 and HB-700. Such forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, market conditions, the failure of customary closing conditions to the asset purchase agreement, the uncertainties inherent in the drug development process, the risk that results of preclinical studies and clinical trials may not be predictive of future results in current or future preclinical and clinical trials, including those for HB-200 and HB-700, the regulatory approval process, the timing of regulatory filings and the challenges associated with manufacturing drug products. Any forward-looking statements and the information in this press release are as of the date of the release, and HOOKIPA undertakes no duty to update these forward-looking statements and information unless required by law. Availability of Other Information About HOOKIPA Investors and others should note that HOOKIPA announces material financial information to investors using the Company’s investor relations website, www.ir.hookipapharma.com, OTC Markets filings, press releases, public conference calls and webcasts. HOOKIPA uses these channels, as well as social media, to communicate with investors and the public about the company, and other issues. It is possible that the information HOOKIPA posts on social media could be deemed to be material information. Therefore, investors, the media, and others interested in HOOKIPA are encouraged to review the information on the social media channels listed on the Company’s investor relations website. For further information, please contact: IR@hookipapharma.com

临床2期免疫疗法快速通道疫苗临床1期

2025-01-06

·生物制药小编

当初诺奖Biotech，现在收购挣扎求生

早先我们介绍过被高瓴清仓，被罗氏退货的Biotech公司HOOKIPA Pharma，现在这家公司又有了新近况，HOOKIPA Pharma正在以全股票交易方式收购专注于罕见病的Poolbeg Pharma，以创建一家合并后的公司，合并之后Hookipa会起头一个3000万美元的私募来为合并后的公司推荐管线。 2023年以来，套着诺奖明星光环的HOOKIPA Pharma境遇不妙，先是首发抗病毒管线毫无效果，接着被罗氏退货，现在公司股价和现金流均亮起红灯，24年年中时，不得不反向分割股票来维持最低上市要求，现在Q3现金及其等价物只有6000万美元左右，按照现行的现金花费速度，在2026年内前就可能无法维持运营。如何一步步跌落谷底从HOOKIPA Pharma的发展历史来看，首发管线失败，被罗氏退货，和临床设计遭到诟病是该公司价值大幅缩水的主要诱因。 HOOKIPA Pharma的核心技术是沙粒病毒，理论上能产生比传统溶瘤单疱病毒更持久，靶向更广泛的效果，该公司首先打算将沙粒病毒用作抗病毒领域。然而，不幸的是，首发管线巨细胞病毒（CMV）疫苗HB-101 II期临床失败，HB-101并没有展现出超过安慰剂的疗效。随后该公司开始转向肿瘤学。然而，肿瘤学临床设计时HOOKIPA Pharma却有些不严谨，该公司管线Eseba-vec（HB-200）治疗HPV16+癌症患者的数据建立在有相当部分患者有K药使用背景。数据看似不错，但是缺乏和K药的对照，后续加增Eseba-vec联合K药vsK药单用的临床为时已晚，无法挽回投资者的信心。至于与罗氏的合作还未开始就胎死腹中，靶向KRAS的HB-700甚至连IND都没来得及申请就被罗氏退货，同时公司因此裁员30%。现在公司的收入来自于吉利德I期临床合作带来的里程碑收入，但是杯水车薪，这些收入仍然不足够弥补推进Eseba-vec需要的花费，而关键节点在于2025年下半年的II期临床关键数据。声称有100亿美元前景，但是账上只有1250万美元…… 而被收购方Poolbeg Pharma的财务状况同样不容乐观，此前我们介绍过英国市场整体环境的不景气，伦敦证交所的AIM（另类投资市场）板块中出现了Biotech的退市潮，英国制药公司根本无法从AIM渠道中融到钱。Poolbeg Pharma反倒是退市潮中坚守的一员。现在这家公司也撑不住了。在2024年7月时，这家公司从OTCQB市场退市，OTCQB市场是美国的场外交易市场专为中小企业和初创企业提供融资和交易平台。这意味着不光光英国市场拿不到钱，现在美国市场也拿不到钱了。糟糕的是，Poolbeg Pharma的财务状况也相当不佳，截止2024年年中时只剩下了1010万英镑，约合1250万美元。然而，在这种情况下，这家公司仍然对自己的管线充满了信心，Poolbeg委托的独立研究更认为核心管线POLB 001有机会扩张出超过100亿美元的市场。因为POLB 001是一种口服片剂，本身的适应症除了治疗病毒感染之外，这家公司主推的适应症就是癌症免疫治疗导致的CRS，当出现CRS后，可能就需要利妥昔单抗托珠单抗，糖皮质激素等应对手段，POLB 001作为口服片剂有机会比双抗和CAR-T中出现CRS应对手段中的其他手段更具有经济性。很显然，且不说未来双抗和CAR-T的市场发展，单从实际情况来看，这一说法多少有点夸大的成分。一方面CAR-T和双抗的CRS本身就具有紧急应对手段，POLB 001想要取而代之，需要临床试验证明使用。但是显然Poolbeg Pharma的资金支撑不到II期临床的第一例患者给药。（2025年下半年）顶线数据则需要等到2026年下半年。这也是这家公司亟需资金的原因。甚至于一些CAR-T和双抗会朝向减少CRS的开发方向发展。因此如果该市场真有如Poolbeg Pharma所吹嘘的那样有100亿美元的前景，那么POLB 001早就被其他大药企看中了。但显然现在的大药企并不会在数据出来之前，对POLB 001操之过急。另外该公司除了POLB 001之外，还有一项人工智能药物发现项目和一款GLP-1R激动剂，基本都处于非常早期阶段。总结总的来看，HOOKIPA Pharma和Poolbeg Pharma其实都缺钱，这次的收购实际上最核心的项目还是其中的3000万美元私募，这可以让这俩家公司至少能拖延到关键节点出数据。即便某个节点失败了，也可以转头去推动另外一个可能成功的管线。参考来源： https://polaris.brighterir.com/public/poolbeg_pharma/news/rns/story/xpvv1qx https://www.globenewswire.com/news-release/2024/11/14/2981605/0/en/HOOKIPA-Pharma-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Recent-Business-Updates.html

并购临床2期疫苗临床1期申请上市

100 项与 Eseba-Vec 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HPV16阳性口咽癌	临床3期	-	Hookipa Biotech AG	2024-12-01
口咽部鳞状细胞癌	临床3期	-	Hookipa Biotech AG	2024-12-01
头颈部鳞状细胞癌	临床2期	美国	HOOKIPA Pharma, Inc.	2022-08-10
HPV相关鳞状细胞癌	临床2期	美国	Hookipa Biotech AG	2019-12-11
HPV相关鳞状细胞癌	临床2期	荷兰	Hookipa Biotech AG	2019-12-11
HPV相关鳞状细胞癌	临床2期	西班牙	Hookipa Biotech AG	2019-12-11
复发性头颈部鳞状细胞癌	临床2期	美国	Hookipa Biotech AG	2019-12-11
复发性头颈部鳞状细胞癌	临床2期	荷兰	Hookipa Biotech AG	2019-12-11
复发性头颈部鳞状细胞癌	临床2期	西班牙	Hookipa Biotech AG	2019-12-11
HPV阳性的口咽鳞状细胞癌	临床前	美国	The University of Chicago	2025-04-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04180215 (AVALON-1, SITC2024) 人工标引	临床2/3期	复发性头颈部鳞状细胞癌一线 PD-L1 High Expression	60	Eseba-vec + Pembrolizumab	觸獵獵鑰鬱獵遞鏇簾製(鏇構網選鹽壓獵構構憲) = 鑰願選蓋糧壓齋齋選構餘鏇鏇淵鑰觸網觸鹹夢 (糧鹹糧構觸衊淵鹽積築 ) 更多	积极	2024-11-05
				Eseba-vec + Pembrolizumab (PD-L1 CPS ≥20)	糧蓋襯遞衊範遞願鹽鏇(餘壓願壓積夢鹽蓋鑰範) = 膚壓範築鹹餘鹹願襯鏇衊願蓋範鬱廠襯簾鏇壓 (選製蓋蓋獵鹽簾餘艱淵 ) 更多
NCT04180215 (GlobeNewswire) 人工标引	临床2期	头颈部肿瘤一线 HPV16 positive	46	HB-200 plus pembrolizumab	窪鬱遞淵膚鹹壓範糧鏇(憲構鹽遞齋衊醖夢蓋築) = 餘鬱構鬱繭選淵願鑰鬱壓窪獵醖窪窪範壓膚積 (淵鏇糧鏇繭構構艱餘遞 ) 更多	积极	2024-06-04
				HB-200 plus pembrolizumab (CPS of 20 or higher)	窪鬱遞淵膚鹹壓範糧鏇(憲構鹽遞齋衊醖夢蓋築) = 艱繭遞壓窪鏇膚遞憲網壓窪獵醖窪窪範壓膚積 (淵鏇糧鏇繭構構艱餘遞 ) 更多
NCT04180215 (ASCO2024) 人工标引	临床2期	头颈部鳞状细胞癌一线 PD-L1 Positive	42	HB-200 plus pembrolizumab	選衊鹽鹽艱夢糧選廠廠(膚構繭築獵衊顧願窪餘) = 壓觸廠餘鹹蓋構衊製醖糧醖廠憲齋鹽襯觸淵淵 (壓顧顧鹹範艱餘窪醖遞 ) 更多	积极	2024-05-24
				HB-200 plus pembrolizumab (PD-L1 CPS ≥20)	餘膚製淵憲繭蓋構憲憲(淵積淵獵餘餘顧壓壓餘) = 觸衊選蓋憲構顧壓齋膚遞齋獵醖鑰夢選鏇選積 (廠網簾築齋窪艱艱醖鬱 ) 更多
NCT05108870 (TARGET-HPV, ASCO2024) 人工标引	临床1期	HPV16阳性口咽癌新辅助 HPV16+	21	HB-201 single vector with chemotherapy	淵網夢憲製餘夢構範醖(願鑰構廠窪鏇遞觸鏇窪) = 餘醖醖壓糧醖範糧築網選餘積繭廠選窪鏇築齋 (網廠簾窪簾選齋糧獵構 )	积极	2024-05-24
				HB-202/201 alternating vector with chemotherapy	淵網夢憲製餘夢構範醖(願鑰構廠窪鏇遞觸鏇窪) = 製積醖蓋醖衊壓製襯積選餘積繭廠選窪鏇築齋 (網廠簾窪簾選齋糧獵構 )
NCT04180215 (SITC2023) 人工标引	临床1期	头颈部肿瘤二线 \| 末线 \| 三线 HPV16-positive	41	HB-200 monotherapy	憲糧壓製簾顧鏇選夢膚(淵鬱積遞窪鬱願衊簾觸) = 衊襯製憲願繭餘鹽蓋衊獵餘積膚鏇蓋網艱顧齋 (選簾襯鹹鹽顧鹹窪憲築 )	积极	2023-11-02
NCT04180215 (ASCO2022) 人工标引	临床1期	HPV相关癌症 HPV16 positive	65	HB-201	製鹹淵廠襯憲選觸齋製(壓願鹽繭膚糧鬱糧窪積) = Preliminary safety, efficacy, and immunogenicity data support IV injection of DL3 (5 × 107 units) every 3 weeks (Q3W) as the RP2D for HB-201 single-vector therapy. RP2D for HB-202/HB-201 will be determined in the very near future. 餘選糧醖鹽製鹽糧鏇願 (齋製膚廠壓簾夢蓋淵築 )	积极	2022-06-02
				HB-202/HB-201
NCT04180215 (GlobeNewswire) 人工标引	临床1/2期	HPV16阳性实体瘤	62	HB-201	窪構壓獵襯艱鏇繭廠簾(蓋艱願夢鑰夢廠遞蓋醖) = 願範製構襯網醖範憲廠淵鹹構夢艱糧襯鹹淵選 (鏇壓積壓顧艱餘構繭襯 ) 更多	积极	2021-11-09
				HB-202/HB-201	窪構壓獵襯艱鏇繭廠簾(蓋艱願夢鑰夢廠遞蓋醖) = 醖鬱顧糧襯蓋鹽獵積鬱淵鹹構夢艱糧襯鹹淵選 (鏇壓積壓顧艱餘構繭襯 ) 更多